Drug Profile
Liprotamase - Alkira Therapeutics
Alternative Names: ALTU-135; Liprotamase; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics
- Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
- Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
- Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Exocrine pancreatic insufficiency
Most Recent Events
- 28 Mar 2018 Anthera Pharmaceuticals has 4 European patents and 16 non-European issued patents for liprotamase
- 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In infants, In adults) in USA (PO) (NCT02823964)
- 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In the elderly, In adults) in USA, United Kingdom, Spain, Poland, Lithuania, Israel, Hungary (PO) (NCT03051490)